1 / 6

Type 2 Diabetes Mellitus Therapeutics in Major Developed Market Forecast to 2021

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets

RamonEMarshall01
Download Presentation

Type 2 Diabetes Mellitus Therapeutics in Major Developed Market Forecast to 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Type 2 Diabetes Mellitus Therapeutics in Developed Markets to 2021 By RnRMarketResearch.com Publisher Name : GBI Research Date: 03-Jul-2015 No. of pages: 179 Single User License: US $4995 Browse more Reports on Diabetes Therapeuticsat http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/diabetes-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 Products Discussed/Mentioned in this Research: Biguanides, Sulfonylureas, Thiazolidinediones, GLP-1 receptor agonists, DPP-4 Inhibitors, SGLT-2 and Insulin Therapies Explore More Research Report on Diabetes Therapeutics Market. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 Scope For Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 • Metformin monotherapy will remain the first-line pharmacotherapy for T2DM. • The emergence of several new drug classes over the past decade, namely the Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP-4) inhibitors, and Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors, has led to considerable market growth. • Which products lead these drug classes and what threats do they face from the pipeline? • How will the continued uptake of newer drug classes impact established drug classes such as the sulfonylureas and thiazolidinediones? • Leading insulin therapy Lantus (insulin glargine) recently lost patent protection in most major markets. • Will recently approved insulin therapies such as Tresiba (insulin degludec) and Toujeo (insulin glargine) be able to capture a significant portion of Lantus' market share? ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 Reasons to Buy: • Understand the clinical context of the T2DM indication and the global burden of the disease by considering epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, disease classification, disease prognosis, and treatment options • Appreciate the current T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need • Identify key pipeline trends in molecule type and molecular target • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related